Amarin Corp Plc (AMRN)

[everyonesguess]

The generics can employ the deny tactics but they have to worry about the treble damage. Now, we are still waiting for the approval of the sNDA, such that let us focus on 11/14 AdCom first, and then let us focus on the approval. With the approval, I think most of the intruders will seek a collective settlement. And Amarin will do what they can do legally.

Or, Amarin has to go to the court for a case of patent infringement (I think Amarin needs one) -- the generics would try to dismiss Vascepa's patents anyway. I believe the court will lead the case to a settlement but generics have to pay certain damage (may not be a treble).

JMHO